Ovary

Germ cell tumors

Monodermal teratomas

Struma ovarii


Editor-in-Chief: Debra L. Zynger, M.D.
Sharon Song, M.D., M.S.
M. Carolina Reyes, M.D.

Last author update: 26 August 2019
Last staff update: 2 May 2024

Copyright: 2002-2024, PathologyOutlines.com, Inc.

PubMed search: Ovary[TIAB] struma ovarii[TI]

Sharon Song, M.D., M.S.
M. Carolina Reyes, M.D.
Page views in 2023: 17,484
Page views in 2024 to date: 6,527
Cite this page: Song S, Reyes MC. Struma ovarii. PathologyOutlines.com website. https://www.pathologyoutlines.com/topic/ovarytumorstruma.html. Accessed May 6th, 2024.
Definition / general
  • Monodermal ovarian teratoma primarily (> 50%) or exclusively composed of benign thyroid tissue
  • Any mature teratoma with malignant thyroid tissue
Essential features
  • Ovarian teratoma either composed predominantly or exclusively of benign thyroid tissue or with any amount of malignant thyroid tissue
  • Most common thyroid malignancy to occur in struma ovarii is papillary thyroid carcinoma, followed by follicular carcinoma
ICD coding
  • ICD-10: D27.9 - benign neoplasm of unspecified ovary
  • ICD-10: C56 - malignant neoplasm of ovary
Epidemiology
  • Most common type of monodermal teratoma
  • Accounts for 3% of ovarian teratomas (Pathol 2007;39:139)
  • Usually presents in the fifth decade
Sites
  • Ovary
Pathophysiology / etiology
  • Unknown at this time
Clinical features
Diagnosis
  • Diagnosis is made by microscopic examination of resected tissue
Laboratory
Radiology description
Radiology images

Images hosted on other servers:

Left adnexal mass

Prognostic factors
  • Most cases have a good prognosis, even when malignancy is present
Case reports
  • 10 year old girl with tachycardia, normal thyroid and thyrotoxicosis with papillary thyroid carcinoma arising from a struma ovarii (Int J Surg Case Rep 2018;51:218)
  • 48 year old woman with malignant struma ovarii presenting 14 years after oophorectomy and chemotherapy (Medicine (Baltimore) 2018;97:e13867)
  • 52 year old woman with clinical features of advanced ovarian carcinoma found to have a struma ovarii (Oncol Lett 2015;9:1739)
  • 61 year old woman with insular carcinoma (90%) and adjacent papillary thyroid carcinoma arising in a struma ovarii (Gynecol Oncol Rep 2016;18:1)
  • 62 year old woman with 2 different types of RAS mutations in a papillary thyroid carcinoma from a struma ovarii and papillary thyroid microcarcinoma of the thyroid (J Endocr Soc 2018;2:944)
  • 74 year old woman with a mixed ovarian tumor composed of elements of Brenner tumor, mucinous cystadenoma and struma ovarii (Int J Gynecol Pathol 2019;38:576)
Treatment
  • Oophorectomy
  • Surgery for malignant struma ovarii may include total abdominal hysterectomy and bilateral salpingo-oophorectomy with complete staging (Gynecol Oncol 2004;94:835)
Gross description
  • Typically unilateral and solid with a gelatinous, red-brown to green cut surface; may show goiter-like multinodular or cystic change (Am J Surg Pathol 1994;18:785)
Gross images

Contributed by Kseniya Korchagina, M.D. and AFIP

Cystic teratoma

Solid and cystic

Reddish brown solid mass

Cystic tumor

Frozen section description
  • Frozen section sample usually shows a mature teratoma or benign thyroid tissue; rarely, a possible malignant component may be detected
Microscopic (histologic) description
  • Variably sized macro and microfollicles often containing colloid
  • Other architectural patterns include solid areas composed of cells with clear to oxyphilic cytoplasm, trabeculae, cords and pseudotubular structures
  • Rarely, stroma in between follicles may be fibrotic or edematous; peripheral stromal leutinization may also be seen
  • Adenomatous hyperplasia or proliferative changes may be seen, such as areas of densely packed follicles or papillary formations lacking nuclear features of papillary thyroid carcinoma
  • Birefringent calcium oxalate crystals may be seen in colloid
  • Most commonly associated malignancy is papillary thyroid carcinoma, cytologically characterized by crowded and overlapping elongated nuclei with irregular contours and chromatin clearing, usually with papillary or follicular architecture
  • Follicular carcinoma is the second most common malignancy; since ovarian lesions typically lack capsule, demonstration of tumor invasion into surrounding ovarian tissue, vascular invasion or metastases is needed as evidence of malignancy
  • Uncommonly associated with the more recently described highly differentiated follicular carcinoma of ovarian origin, characterized by extraovarian spread of thyroid elements histologically resembling nonneoplastic thyroid tissue (Int J Gynecol Pathol 2008;27:213)
  • Undifferentiated (anaplastic) carcinoma and medullary carcinoma have also been described in association with struma ovarii
Microscopic (histologic) images

Contributed by Sharon Song, M.S., M.D., Kseniya Korchagina, M.D. and AFIP

Follicular variant PTC

Capsular invasion

TTF1 stain

Papillary thyroid carcinoma in struma ovarii


Papillary thyroid carcinoma in struma ovarii

Macrofollicular, microfollicular and solid areas

Solid tubular pattern

Oxyphilic cells arranged in nests


With peripheral formation of lutein cells

Resembling clear cell carcinoma

Cystic tumor

Thyroglobulin

With papillary carcinoma

Cytology description
Negative stains
Molecular / cytogenetics description
Sample pathology report
  • Ovary and fallopian tube, left, salpingo-oophorectomy:
    • Struma ovarii, 4.5 cm
  • Ovary and fallopian tube, left, salpingo-oophorectomy:
    • Papillary thyroid carcinoma, follicular and papillary growth patterns, 1.1 cm, arising in a background of struma ovarii
Differential diagnosis
Board review style question #1
What type of crystals may be seen in struma ovarii?

  1. Calcium carbonate
  2. Calcium oxalate
  3. Calcium phosphate
  4. Triple phosphate
  5. Tyrosine
Board review style answer #1
B. Calcium oxalate crystals may be identified in colloid

Comment Here

Reference: Struma ovarii
Board review style question #2
Which laboratory marker may be elevated with struma ovarii?



  1. Alpha-fetoprotein (AFP)
  2. CA125
  3. CEA
  4. hCG
  5. PLAP
Board review style answer #2
B. CA125 is a widely accepted biomarker for ovarian cancers that can also be elevated in many other conditions, such as menstruation, endometriosis, pregnancy, pelvic inflammatory disease, fibroids, liver disease and tumors of the endometrium, breasts and lungs. It can be increased in up to 30% of struma ovarii.

Comment Here

Reference: Struma ovarii
Back to top
Image 01 Image 02